Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Canadian Heart Research Centre | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Eisenmenger Quality Enhancement Research Initiative (QuERI) is a multi-center, observational, US-based longitudinal program, with enrollment of consecutive Eisenmenger patients who meet enrollment. Patient data will be collected prospectively for three years. Individual physician feedback will be provided on data collected with the purpose of improving the management of patients - quality enhancement research initiative (QuERI) process.
Approximately 200 male and female adult patients with a history of Eisenmenger will be recruited from approximately 50 cardiology practices over a period of 18 months and will be followed up every six months for the period of three years. Consecutive patients in each practice meeting inclusion and exclusion criteria should be considered for the study. Participating sites will be asked to maintain a screening log to identify which inclusion or exclusion criteria was not met thus excluding them from the study.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| diagnosis of Eisenmenger Syndrome | subjects with diagnosis of Eisenmenger Syndrome |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Subjects with diagnosis of Eisenmenger Syndrome | Other |
|
| Measure | Description | Time Frame |
|---|---|---|
| Characterization of the clinical course of patients with Eisenmenger Syndrome | The management of Eisenmenger Syndrome patients over the three year registry period will be compared with established national guidelines. In addition, The Minnesota Living with Heart Failure questionnaire (MLHFQ) will be collected. | up to 3 years |
| Measure | Description | Time Frame |
|---|---|---|
| Characterization of the demographics of patients with Eisenmenger Syndrome | baseline (visit 1) thru end of study (3 years) | |
| Identification of clinical predictors of short-term and long-term outcomes of patients with Eisenmenger Syndrome. | baseline (visit 1) thru end of study (3 years) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
200 adult patients with Eisenmenger Syndrome recruited from approximately 50 US cardiology practices.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Michael Landzberg, MD | Harvard Medical School / Boston Adult Congenital Heart | Study Chair |
| Gary Palmer, MD, MBA | Actelion Pharmaceuticals U.S., Inc. | Study Director |
Not provided
| ID | Term |
|---|---|
| D000081029 | Pulmonary Arterial Hypertension |
| D004541 | Eisenmenger Complex |
| ID | Term |
|---|---|
| D006976 | Hypertension, Pulmonary |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D006330 | Heart Defects, Congenital |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood samples will be collected at Baseline and at each of the annual visits. In addition, urine sampling will be performed at Baseline. An analysis of biomarkers will be performed at a hospital core laboratory.
|
|
| Characterization of patients treated with PAH-specific medications to patients untreated with PAH-specific medications. | baseline (visit 1) thru end of study (3 years) |
| D018376 | Cardiovascular Abnormalities |
| D002318 | Cardiovascular Diseases |
| D006331 | Heart Diseases |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |